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Background: The aim of the present study was to analyse the outcome after hepatic resection for
non-colorectal, non-neuroendocrine, non-sarcomatous (NCNNNS) metastatic tumours and to identify the
factors predicting survival.
Methods: All patients who underwent hepatic resection for NCNNNS metastatic tumours between
September 1996 and June 2009 were included. Patients' demographics, clinical and histopathological
parameters, overall survival and the factors predicting survival were analysed.
Results: In all, 65 patients underwent hepatic resection for metastasis. The most common site of a
primary tumour was the kidney (24 patients). Fifteen patients had synchronous tumours. Fifty patients had
major liver resections and 22 patients had bilobar disease. The median number of liver lesions resected
was 1 and the median maximum diameter of the metastasis was 6 cm. A R0 resection was performed in
51 patients. The 1-, 3- and 5-year overall survival from the time of metastasectomy was 72.9%, 47.9%
and 25.6%, respectively, with a median survival of 19 months. The presence of a tumour of greater than
6 cm (P = 0.048) and a positive resection margin (P = 0.04) were associated with poor survival.
Conclusion: Hepatic resection for metastasis from NCNNNS tumours can offer acceptable long-term
survival in selected patients. To offer a chance of a cure a R0 resection must be performed.
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Introduction
Hepatic resection is an accepted form of treatment for patients
with liver metastasis from colorectal cancer. The reported 5-year
survival rates range from 16% to 51% depending on patient
selection.1–4 Recent studies have shown that hepatic metastasec-
tomy for colorectal cancer metastasis is associated with a good
chance of long-term survival.5,6
Similarly the role of liver resection is widely accepted for
metastasis from neuroendocrine tumours, both for symptomatic
control and improvement in survival.7–10 Liver resection is
appealing in this group of patients because these cancers typically
metastasize through the portal venous system similar to colorectal
cancers and have a protracted natural history compared with
other gastrointestinal cancers and solid tumours. A 5-year survival
rate of up to 75% has been reported after hepatic resection.11,12
More recently, liver resection is being increasingly performed
for metastasis from soft tissue sarcomas. Several studies have
shown a promising 5-year survival rate of 27% to 49% after
hepatic resection for metastatic sarcoma.13–15
However, the role of liver resection remains ill defined and
controversial for patients with metastasis from non-colorectal,
non-neuroendocrine, non-sarcomatous (NCNNNS) tumours.
Although several studies have been published recently, the results
are inconsistent as a result of the heterogeneity of the study
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group.16–19 Most of the studies included patients with metastasis
from soft tissue sarcomas and this may significantly influence the
results of these studies. Moreover, limited data are available from
centres in the United Kingdom (UK).20 Hence, the present study
was performed to analyse the outcome after hepatic resection for
NCNNNS metastasis and to define the factors predicting survival
to facilitate appropriate patient selection.
Patients and methods
All patients who underwent hepatic resection for NCNNNS
metastasis between September 1996 and June 2009 at the Univer-
sity Hospital of Birmingham NHS Foundation Trust were included
in the present study. The data were obtained from the prospectively
maintained hospital-based liver unit and pathology database.
Selection criteria
Liver resection was considered if all known disease was technically
resectable with an adequate hepatic functional reserve and if the
general condition of the patient permitted liver resection. Pre-
operatively all patients underwent a computerized tomographic
(CT) scan of the thorax, abdomen and pelvis with contrast and/
or magnetic resonance imaging (MRI) of the liver. Radiological
images were discussed in a multi-disciplinary meeting (MDM)
involving surgeons, oncologists, radiologists and pathologists.
Further imaging, in the form of a positron emission tomography
(PET)-CT, was performed based on the outcome of the MDM.
Patients with a primary tumour infiltrating into the liver were
excluded from the study. The presence of resectable extrahepatic
disease did not preclude liver resection.
Follow-up
Post-operatively, all patients were followed up radiologically, clini-
cally and biochemically up to the fifth post-operative year. Clinical
and biochemical surveillance was performed every 3 months for
the first year, every 4 months for the second year, every 6 months
for the third year and yearly thereafter until the fifth post-
operative year. A CT scan of the chest, abdomen and pelvis was
done annually up to 5 years after surgery. Tumour markers were
measured as appropriate based on the type of primary tumour.
Variables
Patient demographics, tumour characteristics, clinical and opera-
tive parameters were analysed. The following variables were
assessed as prognostic factors: age (59 vs. >59 years, the median
age being 59 years), gender (male vs. female), site of the primary
tumour (renal cell carcinoma vs. others, genital tumours vs.
others, genitourinary tumours vs. others), time of occurrence of
metastases (synchronous vs. metachronous), interval between
surgery for a primary tumour and liver resection (<30 months vs.
30 months), number of metastases (1 vs. >1), maximum diam-
eter of the metastasis (6 cm vs. >6 cm), presence of resectable
extrahepatic disease (yes vs. no), type of liver resection (<3
segments vs. 3 segments), site of metastases (bilobar vs. unilo-
bar) and status of the resection margin (negative margin vs.
involved margin). As the median maximum tumour diameter was
6 cm and the median time interval between the primary and liver
surgery was 30 months, these were used as a cut-off for analysis as
binary variables. As a result of variation in the type, timing and
duration of chemotherapy, it was not analysed as a variable in this
study.
Synchronous liver lesions were defined as the simultaneous
development of a primary tumour and liver metastasis or the
occurrence of liver metastasis within 3 months of resection of the
primary tumour. A R0 resection was defined as the presence of a
negative microscopic resection margin and R1 as a positive micro-
scopic resection margin.
The overall actuarial 1-, 3- and 5-year survival was calculated
from the time of hepatic metastasectomy. Mortality data were
described as 30-, 60- and 90-day mortality.
Statistics
The overall survival was calculated with survival curve analysis
using the Kaplan–Meier method. Survival comparison between
the high-risk groups was compared with a log-rank test and the
significance was assigned at 0.05. The statistical programme for
social statistics (SPSS version 17.0; SPSS Inc., Chicago, IL, USA)
was used for statistical analysis.
Results
Clinical and pathological features
In all, 65 patients underwent liver resection for metastasis from
NCNNNS tumours, between September 1996 and June 2009. At
the time of hepatic resection, the median age was 59 years (range:
23–75 years). There were 25 men and 40 women.
The most common site of a primary tumour was the kidney,
seen in 24 patients (36.9%). The sites of other primary tumours
are shown in Table 1. The histology of the testicular cancer
was choriocarcinoma, that of thyroid cancer was follicular carci-
noma and the cutaneous and eye tumours were melanomas. In
15 patients (23.1%), a synchronous liver lesion was identified,
whereas the remaining 50 patients (76.9%) had metachronous
liver metastasis. The median interval between resection of a
primary tumour and liver resection was 30 months (range: 0–463
months) for the entire cohort and 48 months for those with
metachronous lesions.
The type of surgical resection was based on the need of each
individual patient, as discussed at the MDM. The different hepatic
resections performed were a right hemihepatectomy (n = 26,
40%), an extended right hepatectomy (n = 11, 16.9%), a right
hepatectomy with non-anatomical resection (NAR) (n = 6, 9.2%),
a left hepatectomy (n = 2, 3.1%), an extended left hepatectomy
(n = 1, 1.5%), a left lateral segmentectomy (n = 3, 4.6%), a left
lateral segmentectomy with NAR (n = 2, 3.1%) and NAR alone
(n = 14, 21.5%). Major liver resection, defined as resection of more
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than three Couinaud’s segments, was undertaken in 50 patients
(76.9%). Twenty-two patients (33.8%) were found to have bilobar
disease.
Significant morbidity after liver resection was seen in 15
patients. One patient had intra-abdominal bleeding requiring
re-laparotomy. One patient developed a bile leak. This was
managed by biliary stenting and percutaneous drainage. Two
patients had a wound infection requiring drainage. Two patients
developed intra-abdominal collection, necessitating percutaneous
radiological guided drainage. A chest infection was seen in five
patients. Small-for-size syndrome and renal failure were seen in
two patients each. Both the patients with renal failure needed
renal replacement therapy.
Final histological examination of the resected specimen con-
firmed the number of liver lesions to range from 1 to 7, the
median being 1. The majority of patients had a solitary metastasis
(n = 47, 72.3%). Further data on the number of liver metastases
are shown in Table 2. The median maximum diameter of the
largest lesion was 6 cm, ranging from 1.5 to 16 cm.
A R0 resection was successfully achieved in 51 patients (78.5%),
while the remaining 14 patients (21.5%) had a R1 resection. There
was no difference between the R0 and R1 resections with respect
to the number of liver metastases (median of 1 vs. 1.5), size of
metastases (median of 6 cm vs. 7 cm) and type of liver resection
(37 major, 14 minor vs. 13 major, 1 minor). In no patients was a
gross tumour left behind (R2 resection).
Extrahepatic disease
Resectable extrahepatic disease at the time of liver resection was
seen in 19 patients (29.2%). The sites of extrahepatic disease were
the diaphragm (6 patients), peritoneal nodule (4 patients), dia-
phragm, omentum and peritoneum (1 patient), omentum (1
patient), diaphragm and adrenal (2 patients), adrenal (1 patient),
pancreas (1 patient), right lower lobe of the lung (1 patient),
lymph node (1 patient) and pelvic recurrence (1 patient). Twelve
patients had R0 resection and the remaining seven patients had R1
resection.
Recurrence
The disease-free interval before liver resection for the 50 patients
with metachronous liver metastases ranged from 4 to 463 months,
with a median of 48 months. The median disease-free interval
after liver resection of the entire cohort was 19 months.
Five patients had extrahepatic disease recurrence before liver
resection. One patient developed axillary nodal recurrence,
requiring axillary clearance, two and a half years after excision of
a primary cutaneous melanoma. This was followed by liver resec-
tion for metastasis 6 months later. The second patient had en bloc
resection of a distal pancreas, spleen and lymph node for extensive
retroperitoneal recurrence, 5 years after resection of testicular
cancer. This patient subsequently had a NAR of a segment IV liver
metastasis a year later. A third patient had resection of abdominal
wall recurrence 10 years after excision of primary ovarian cancer,
followed by groin lymphadenectomy 9 years later and a subse-
quent liver resection 2 years later. Another patient developed renal
bed recurrence, requiring excision, 8 years after nephrectomy. This
was followed by liver resection for metastasis a year later. Axillary
nodal recurrence was noticed in another patient 2 years after a
mastectomy for primary breast cancer. This patient subsequently
developed a liver metastasis 7 years later, requiring resection.
One patient had repeat liver resection for recurrent disease
within the liver. This patient had a right hemihepatectomy and
NAR of a segment 2 lesion for a synchronous metastasis from a
primary renal cell carcinoma. This patient developed recurrence
in segment 3 of the liver 10 months later, requiring another NAR.
Survival
The median overall survival, calculated from the time of hepatic
metastasectomy, was 19 months, ranging from 0 to 125 months
(Fig. 1). The 1-, 3- and 5-year survival rates were 72.9%, 47.9%
and 25.6%, respectively. There was no peri-operative mortality.
Six patients (9.2%) died within 30 days of liver resection. All of
them died of multi-organ failure. The 60- and 90-day mortalities
were eight patients (12.3%) each. Comparison of cancer-specific
Table 1 Sites of primary tumours in patients who underwent liver
resections for metastases
Primary tumour site n (%)
Kidney 24 (36.9)
Ovary 16 (24.6)
Uterus 3 (4.6)
Adrenal 2 (3.1)
Testis 1 (1.5)
Bile duct 1 (1.5)
Jejunum 1 (1.5)
Oropharynx 1 (1.5)
Breast 6 (9.2)
Thyroid 3 (4.6)
Eye 1 (1.5)
Skin 4 (6.2)
Lungs 2 (3.1)
Table 2 The number of liver lesions in patients who underwent
metastasectomy for non-colorectal, non-neuroendocrine, non-
sarcoma metastases
Number of liver metastases Number of patients (%)
1 47 (72.3)
2 6 (9.2)
3 6 (9.2)
4 2 (3.1)
5 1 (1.5)
6 1 (1.5)
7 2 (3.1)
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survival revealed a median survival of 22.5 months for renal cell
carcinoma, 23 months for genital tumours and 22.5 months for
genitourinary tumours.
Prognostic factors
Among all the factors which were analysed to predict survival on
univariate analysis, two variables, namely metastatic tumour size
of >6 cm (P = 0.048) and R1 resection (P = 0.04), were found to be
associated with a significantly poor outcome (Figs 2,3, Table 3).
The negative predictive factors were further individually analysed
to define their impact on 5-year survival. The 5-year survival
dropped from 44.4% for a tumour of 6 cm to 13.6% for a
tumour of >6 cm. Similarly, the 5-year survival was 32.1% for a R0
resection, in contrast to 16.7% for a R1 resection. However on
multivariate analysis, none of the variables were found to signifi-
cantly affect outcome.
Interestingly, the presence of resectable extra-hepatic disease
did not influence outcome (Table 3). The median survival for
those with extra-hepatic disease was 15 months (range: 0 to 125
months) compared with 21 months for those without (range: 0 to
120 months).
Discussion
The present study analysed the long-term results of patients
undergoing hepatic resection for NCNNNS metastasis over a
period of 13 years from a high-volume single centre. Patients with
metastatic sarcoma were excluded from the present study for two
reasons. First, sarcomas are a heterogenous group of tumours of
mesenchymal origin with a completely different tumour biology.
Second, studies have shown promising 5-year survival rates for
patients undergoing liver resection for metastatic sarcomas and
have concluded that surgery should be considered if the hepatic
metastasis is functionally and technically resectable.13–15
The results from the present study show that an aggressive
surgical approach was associated with a significant long-term
Overall survival
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Figure 1 A cumulative survival curve for patients who underwent a
liver resection for metastases, calculated from the time of hepatic
metastasectomy
Figure 2 Cumulative survival curves comparing metastases size of
6 and >6 cm
Figure 3 Cumulative survival curves comparing R0 andR1 resections
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survival, resulting in one-quarter of all patients surviving up to 5
years. The 5-year survival reported in the literature ranges from
17% to 38%,17,19–27 although most of the studies included metasta-
sis from endocrine tumours and sarcomas (Table 4). Hence direct
comparison of this cohort with the published data cannot be
made as a result of the heterogeneity of the study population.
However, in order to have a meaningful comparison, survival for
the entire population of patients who had liver resection for non-
colorectal and non-neuroendocrine metastases in the study centre
was calculated. This group had a median survival of 22 months
and a 5-year survival of 29.03%.
Patient selection is vital to any treatment and it continues to
pose a challenge with respect to liver resection for NCNNNS
metastasis. A number of previous studies have reported different
prognostic variables associated with survival and are summa-
rized in Table 4. The present study found a significant correla-
tion between tumour size, resection margin status and survival
on univariate analysis. A maximum diameter of a metastatic
lesion of >6 cm (P = 0.048) and a positive microscopic resection
margin (P = 0.04) were associated with poor survival. However,
on multivariate analysis these variables were not found to be
significant. This could be attributed to the small sample size.
O’Rourke et al. and Ercolani et al. confirmed that a metastatic
tumour size of >5 cm had a negative influence on survival.20,22
Patients with larger tumours should be considered for downsiz-
ing chemotherapy before liver resection. Unfortunately, the
precise role of chemotherapy could not be ascertained in
the present study as a result of the heterogenous nature of the
tumour type and the different types and timing of chemo-
therapy. Schmelzle et al. studied the role of liver resection in 44
patients with NCNNNS metastasis and found adjuvant chemo-
therapy to be an independent prognostic variable associated
with better survival.21 Fifty-five per cent of patients in their
study received chemotherapy. However, the precise nature of the
chemotherapy was not mentioned. In the study by Reddy et al.,
46% of patients received pre-operative chemoradiotherapy and
51% received post-operative chemoradiotherapy. It was found
that chemoradiotherapy significantly improved survival on
univariate analysis.25 However, this did not reach significance on
multivariate analysis.
A number of studies have found the site of the primary tumour
to significantly affect survival.17,19,24 In general, metastases from
genitourinary and breast tumours have a better prognosis than
other primary tumours. Gastrointestinal primary tumours spe-
cifically are associated with a worse outcome. This highlights
the significance of individual tumour biology. In the present
study genitourinary tumours were compared with other primary
tumours, renal cell carcinomas alone with other tumours and
genital tumours alone with other tumours and did not find any
significant correlation with survival. This could possibly be as a
result of the small size of the study group or because of the
confounding effect of adjuvant therapy.
The disease-free interval was another commonly described
prognostic indicator in many reported series,17,19,21,22,26,27 although
the duration of the interval varied in different studies. In essence,
the longer the disease-free interval, the better was the prognosis.
This correlates with the assertion that the tumour which metas-
tasizes later is likely to be less aggressive than those that spread
early. In the present study, analysis was performed to identify
any association with survival of the time interval between primary
surgery and liver resection and failed to show any correlation. As
the median time interval was 30 months, this was used as the
cut-off for the purpose of analysis.
An important factor that has to be taken into consideration
during liver resection for metastasis is the chance of achieving
microscopic negative resection margins. In the present study, a R0
resection was associated with a significantly better outcome. This
is in agreement with the results reported in other series.19,23,24
The presence of resectable extrahepatic disease did not influ-
ence the outcome in the present study. This is possibly because all
the patients had either a R0 or R1 resection of the extra-hepatic
disease and no gross tumour was left behind. Moreover, all but one
patient had extrahepatic disease within the abdominal cavity. Ng
et al. reported that the presence of a resectable extrahepatic intra-
abdominal metastasis carries a better prognosis compared with
extra-abdominal metastasis.28 It is vital that all extrahepatic
disease is sought pre-operatively in order to make a decision about
resectability.
The limitations of the present study include the small patient
population size and the retrospective nature of the study, although
the data were collected prospectively. Also, the inclusion of a
highly selected cohort of patients, who are likely to have favour-
able tumour biology and are unlikely to represent the general
population of patients with metastasis from NCNNNS tumours.
Despite the limitations, this study does provide a reasonable
conclusion in this group of patients. Although many reports have
Table 3 Univariate analysis of variables predicting outcome after
hepatic metastasectomy
Variables P-value Hazard
ratio
Age, 59 vs. >59 years 0.79 0.024
Gender, male vs. female 0.09 0.515
Primary tumour, renal vs. others 0.294 0.000
Synchronous vs. metachronous 1.0 0.000
Interval between primary and liver resection,
<30 vs. 30 months
0.413 0.000
Number of metastases, 1 vs. >1 0.201 0.334
Size of metastases, 6 vs. >6 cm 0.048a 1.175
Extrahepatic disease, present vs. absent 0.778 0.020
Type of resection, major vs. minor 0.08 0.713
Bilobar vs. unilobar metastases 0.204 0.330
Resected margin, positive vs. negative 0.04a 1.538
aStatistically significant.
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been published on this subject recently, there are only a few from
the centres in the UK
In conclusion, hepatic resection for metastasis from NCNNNS
tumours can offer acceptable long-term survival in selected
patients. To offer a chance of a cure a R0 resection must be per-
formed. However, caution should be exercised in patients with
large metastatic tumours, as it is not associated with significant
long-term survival. The presence of extrahepatic disease should
not be considered a contraindication for liver resection, provided
the extrahepatic disease is resectable.
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